| Entry |
|
|---|
| Name |
FGFR3 erdafitinib-susceptible variation
|
|---|
| Type |
Gain of function
|
|---|
| Gene |
|
|---|
| Organism |
hsa_var Human gene variants (Homo sapiens)
|
|---|
| Variation |
FGFR3-TACC3 fusion, translocation t(4;4)(q16;q16) |
|---|
| Variation |
FGFR3-BAIAP2L1 fusion, translocation t(4;7)(p16;q22) |
|---|
| Network |
|
|---|
| Disease |
|
|---|
| Drug target |
|
|---|
| Reference |
|
|---|
| Authors |
Marandino L, Raggi D, Giannatempo P, Fare E, Necchi A |
|---|
| Title |
Erdafitinib for the treatment of urothelial cancer. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Nadal R, Bellmunt J |
|---|
| Title |
Management of metastatic bladder cancer. |
|---|
| Journal |
|
|---|
| LinkDB |
|
|---|
